NASDAQ:MGTX - MeiraGTx Stock Price, Forecast & News

MeiraGTx trades on the NASDAQ under the ticker symbol "MGTX."

MeiraGTx Holdings PLC (NASDAQ:MGTX) posted its quarterly earnings results on Thursday, November, 7th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.53) by $0.23. The company earned $3.58 million during the quarter. View MeiraGTx's Earnings History.

MeiraGTx is scheduled to release their next quarterly earnings announcement on Tuesday, March 24th 2020. View Earnings Estimates for MeiraGTx.

3 analysts have issued 1-year price objectives for MeiraGTx's shares. Their forecasts range from $30.00 to $45.00. On average, they anticipate MeiraGTx's share price to reach $38.33 in the next year. This suggests a possible upside of 103.0% from the stock's current price. View Analyst Price Targets for MeiraGTx.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MeiraGTx in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MeiraGTx.

News articles about MGTX stock have trended somewhat positive recently, InfoTrie reports. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. MeiraGTx earned a news impact score of 1.8 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for MeiraGTx.

MeiraGTx saw a increase in short interest in January. As of January 15th, there was short interest totalling 841,500 shares, an increase of 11.4% from the December 31st total of 755,700 shares. Based on an average trading volume of 156,600 shares, the short-interest ratio is presently 5.4 days. Approximately 3.2% of the shares of the company are short sold. View MeiraGTx's Current Options Chain.

Some companies that are related to MeiraGTx include Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Alector (ALEC), Regenxbio (RGNX), Cortexyme (CRTX), Coherus Biosciences (CHRS), Editas Medicine (EDIT), SpringWorks Therapeutics (SWTX), I-Mab (BDTX), Orchard Therapeutics (ORTX), NanoString Technologies (NSTG), Krystal Biotech (KRYS), Twist Bioscience (TWST), Adverum Biotechnologies (ADVM) and BAVARIAN NORDIC/S (BVNRY).

Based on aggregate information from My MarketBeat watchlists, some companies that other MeiraGTx investors own include AbbVie (ABBV), Kadmon (KDMN), Crispr Therapeutics (CRSP), Fate Therapeutics (FATE), InVitae (NVTA), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), Galmed Pharmaceuticals (GLMD), Intercept Pharmaceuticals (ICPT) and Agile Therapeutics (AGRX).

(MGTX) raised $75 million in an initial public offering on Friday, June 8th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Barclays and Evercore ISI served as the underwriters for the IPO and Chardan was co-manager.

MeiraGTx's stock is owned by many different of institutional and retail investors. Top institutional shareholders include State Street Corp (0.93%), Alyeska Investment Group L.P. (0.91%), Rhenman & Partners Asset Management AB (0.52%), Sectoral Asset Management Inc (0.26%), Schonfeld Strategic Advisors LLC (0.24%) and Parkman Healthcare Partners LLC (0.23%). Company insiders that own MeiraGTx stock include Alexandria Forbes, Life Sciences Maste Perceptive, Nicole Seligman and Richard Giroux. View Institutional Ownership Trends for MeiraGTx.

MGTX stock was sold by a variety of institutional investors in the last quarter, including Sectoral Asset Management Inc, Panagora Asset Management Inc., Alyeska Investment Group L.P., Renaissance Technologies LLC, Russell Investments Group Ltd., Goldman Sachs Group Inc. and Meeder Asset Management Inc.. Company insiders that have sold MeiraGTx company stock in the last year include Alexandria Forbes and Richard Giroux. View Insider Buying and Selling for MeiraGTx.

MGTX stock was bought by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Parkman Healthcare Partners LLC, California Public Employees Retirement System, Acadian Asset Management LLC, Schonfeld Strategic Advisors LLC, State Street Corp, Claraphi Advisory Network LLC and Private Advisors LLC. Company insiders that have bought MeiraGTx stock in the last two years include Life Sciences Maste Perceptive and Nicole Seligman. View Insider Buying and Selling for MeiraGTx.

Shares of MGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MGTX stock can currently be purchased for approximately $18.88.

MeiraGTx has a market capitalization of $690.44 million. The company earns $-82,870,000.00 in net income (profit) each year or ($4.39) on an earnings per share basis. MeiraGTx employs 68 workers across the globe.View Additional Information About MeiraGTx.

The official website for MeiraGTx is http://www.meiragtx.com/.

MeiraGTx's mailing address is 450 East 29thStreet 15thFloor, NEW YORK NY, 10016. The company can be reached via phone at 646-860-7985 or via email at [email protected]